JP2017533946A5 - - Google Patents

Download PDF

Info

Publication number
JP2017533946A5
JP2017533946A5 JP2017526527A JP2017526527A JP2017533946A5 JP 2017533946 A5 JP2017533946 A5 JP 2017533946A5 JP 2017526527 A JP2017526527 A JP 2017526527A JP 2017526527 A JP2017526527 A JP 2017526527A JP 2017533946 A5 JP2017533946 A5 JP 2017533946A5
Authority
JP
Japan
Prior art keywords
methyl
amino
carboxamide
pyrazine
oxazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017526527A
Other languages
English (en)
Japanese (ja)
Other versions
JP6779204B2 (ja
JP2017533946A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/060509 external-priority patent/WO2016081290A1/en
Publication of JP2017533946A publication Critical patent/JP2017533946A/ja
Publication of JP2017533946A5 publication Critical patent/JP2017533946A5/ja
Application granted granted Critical
Publication of JP6779204B2 publication Critical patent/JP6779204B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017526527A 2014-11-18 2015-11-13 A2a拮抗薬特性を有するアミノピラジン化合物 Expired - Fee Related JP6779204B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462081262P 2014-11-18 2014-11-18
US62/081,262 2014-11-18
PCT/US2015/060509 WO2016081290A1 (en) 2014-11-18 2015-11-13 Aminopyrazine compounds with a2a antagonist properties

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020138418A Division JP2020193211A (ja) 2014-11-18 2020-08-19 A2a拮抗薬特性を有するアミノピラジン化合物

Publications (3)

Publication Number Publication Date
JP2017533946A JP2017533946A (ja) 2017-11-16
JP2017533946A5 true JP2017533946A5 (enExample) 2018-12-20
JP6779204B2 JP6779204B2 (ja) 2020-11-04

Family

ID=56014406

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017526527A Expired - Fee Related JP6779204B2 (ja) 2014-11-18 2015-11-13 A2a拮抗薬特性を有するアミノピラジン化合物
JP2020138418A Withdrawn JP2020193211A (ja) 2014-11-18 2020-08-19 A2a拮抗薬特性を有するアミノピラジン化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020138418A Withdrawn JP2020193211A (ja) 2014-11-18 2020-08-19 A2a拮抗薬特性を有するアミノピラジン化合物

Country Status (11)

Country Link
US (1) US10472347B2 (enExample)
EP (1) EP3220910B1 (enExample)
JP (2) JP6779204B2 (enExample)
KR (1) KR20170083136A (enExample)
CN (1) CN107106558A (enExample)
AU (1) AU2015350315B2 (enExample)
BR (1) BR112017010261A2 (enExample)
CA (1) CA2967944C (enExample)
MX (1) MX381180B (enExample)
RU (1) RU2727805C2 (enExample)
WO (1) WO2016081290A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116478131A (zh) * 2016-07-12 2023-07-25 锐新医药公司 作为变构shp2抑制剂的2,5-双取代型及2,5,6-三取代型3-甲基吡嗪
CN110431134A (zh) 2017-01-23 2019-11-08 锐新医药公司 作为变构shp2抑制剂的吡啶化合物
AU2018210770B2 (en) 2017-01-23 2022-03-24 Revolution Medicines, Inc. Bicyclic compounds as allosteric SHP2 inhibitors
JP7071389B2 (ja) * 2017-03-07 2022-05-18 グアンジョウ マキシノベル ファーマシューティカルズ カンパニー リミテッド アミノピリミジン縮合5員複素環化合物、その中間体、製造方法、薬物組成物および使用
EP3654982A4 (en) 2017-07-18 2021-04-14 Nuvation Bio Inc. 1,8-NAPHTHYRIDINONE COMPOUNDS AND THEIR USES
EP3654978A4 (en) 2017-07-18 2021-03-31 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS USED AS ADENOSINE ANTAGONISTS
AU2018325451A1 (en) 2017-08-31 2020-03-05 Corvus Pharmaceuticals, Inc. Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor
KR20200070295A (ko) 2017-10-12 2020-06-17 레볼루션 메디슨즈, 인크. 알로스테릭 shp2 억제제로서의 피리딘, 피라진 및 트리아진 화합물
EP3723754A4 (en) 2017-12-13 2021-05-19 Merck Sharp & Dohme Corp. IMIDAZO [1,2-C] QUINAZOLINE-5-AMINE COMPOUNDS WITH PROPERTIES OF A2A ANTAGONIST
CN111433205B (zh) 2017-12-15 2024-01-19 锐新医药公司 作为变构shp2抑制剂的多环化合物
US11572360B2 (en) 2018-08-16 2023-02-07 Innate Tumor Immunity, Inc. Substituted 4-amino-1H-imidazo[4,5-c]quinoline compounds and improved methods for their preparation
US20200079793A1 (en) * 2018-08-31 2020-03-12 Corvus Pharmaceuticals, Inc. Compounds and methods for modulating adenosine a2b receptor and adenosine a2a receptor
WO2020106558A1 (en) 2018-11-20 2020-05-28 Merck Sharp & Dohme Corp. Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
EP3883576B1 (en) 2018-11-20 2025-12-17 Merck Sharp & Dohme LLC Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
MX2021006012A (es) 2018-11-30 2021-07-06 Merck Sharp & Dohme Derivados de amino triazolo quinazolina 7-, 8-, y 10-sustituidos como antagonistas de receptor de adenosina, composiciones farmaceuticas y su uso.
JOP20210117A1 (ar) 2018-11-30 2023-01-30 Merck Sharp & Dohme مشتقات أمينو ترايازولو كوينازولين بها استبدال في الموضع-9 كمضادات مستقبل أدينوزين، تركيبات صيدلانية واستخدامها
SG11202106963YA (en) 2019-01-11 2021-07-29 Omeros Corp Methods and compositions for treating cancer
US11254670B2 (en) 2019-01-18 2022-02-22 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
MX2021008650A (es) 2019-01-18 2021-11-03 Nuvation Bio Inc Compuestos heterociclicos como antagonistas de adenosina.
TW202128650A (zh) * 2019-10-11 2021-08-01 德商拜耳動物保健有限公司 作為殺蟲劑之新穎的雜芳基取代之吡𠯤衍生物
CN111285798A (zh) * 2020-04-09 2020-06-16 阿里生物新材料(常州)有限公司 一种(3-环丙基吡啶-2-基)甲胺盐酸盐的合成方法
CN111423364A (zh) * 2020-05-19 2020-07-17 阿里生物新材料(常州)有限公司 一种(3-环丙基吡啶-2-基)甲胺的合成方法
EP3929189A1 (en) * 2020-06-25 2021-12-29 Bayer Animal Health GmbH Novel heteroaryl-substituted pyrazine derivatives as pesticides
AU2022241754A1 (en) 2021-03-23 2023-10-19 BioAge Labs, Inc. Inhibitors of nlrp3 inflammasome
WO2023147468A1 (en) 2022-01-28 2023-08-03 BioAge Labs, Inc. N-oxide inhibitors of nlrp3 inflammasome
KR20250004779A (ko) 2022-04-13 2025-01-08 길리애드 사이언시즈, 인코포레이티드 Trop-2 발현 암을 치료하기 위한 병용 요법
US12516018B2 (en) * 2023-03-30 2026-01-06 Brandeis University Solid-solid phase change aromatic azo compounds, method of manufacture, and use for thermal energy storage and release
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025207644A1 (en) 2024-03-26 2025-10-02 BioAge Labs, Inc. Inhibitors of nlrp3 inflammasome

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
EP0666079B1 (en) 1993-07-27 2001-11-07 Kyowa Hakko Kogyo Co., Ltd. Remedy for parkinson's disease
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
SK287748B6 (sk) 2000-05-26 2011-08-04 Schering Corporation Substituované 5-amino-pyrazolo[4,3-e]-1,2,4-triazolo[1,5- c]pyrimidíny, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie
SE0203754D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
EP1641779A1 (en) 2003-06-18 2006-04-05 AstraZeneca AB 2-substitued 5, 6-diaryl-pyrazine derivatives as cb1 modulator.
WO2005040151A1 (en) * 2003-10-27 2005-05-06 Astellas Pharma Inc. Pyrazine derivatives and pharmaceutical use thereof
US20060199828A1 (en) 2005-03-04 2006-09-07 Georg Jaeschke Pyrazine-2-carboxyamide derivatives
ES2270715B1 (es) * 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
WO2010141275A1 (en) * 2009-06-01 2010-12-09 Merck Sharp & Dohme Corp. Pyrazine carboxamide orexin receptor antagonists

Similar Documents

Publication Publication Date Title
JP2017533946A5 (enExample)
RU2017120853A (ru) Аминопиразиновые соединения со свойствами антагониста a2a
JP4672820B2 (ja) GABAα5リガンドとしての置換1,2,4−トリアゾロ[3,4−a]フタラジン誘導体
KR101819433B1 (ko) 인돌린-2-온 또는 피롤로-피리딘-2-온 유도체
US9321756B2 (en) Azole compounds as PIM inhibitors
MX2011012345A (es) Inhibidores de pi3k/mtor basados en benzoxazepinas contra enfermedades proliferativas.
JP2016500073A5 (enExample)
CN111556871B (zh) 作为PDE1抑制剂的1H-吡唑并[4,3-b]吡啶
JP2013527173A5 (enExample)
JP2013508404A5 (enExample)
JP2017530960A5 (enExample)
RU2007101544A (ru) Антагонисты рецепторов высвобождающего гонадотропин гормона
JP2013508403A5 (enExample)
ME02437B (me) Disupstituirani oktahidropirolo[3,4-c]piroli kao modulatori oreksin receptora
EP2424859A1 (en) Inhibitors of pi3 kinase and / or mtor
ME02802B (me) P2x7 modulatori
AU2011338389A1 (en) Bicyclic compounds as Pim inhibitors
JP2013508405A5 (enExample)
RU2015114936A (ru) Ингибиторы серин/треонинкиназы
CN120826403A (zh) Shp2抑制剂化合物及其应用
KR101898364B1 (ko) 인돌린-2-온 및 1,3-다이하이드로-피롤로[3,2-c]피리딘-2-온 유도체
KR20150047609A (ko) 피리딘 유도체 및 의약
CN114502537A (zh) 突变型idh2抑制剂及其应用
RU2015125306A (ru) Новые соединения ингибиторы фосфодиэстеразы типа 10а
RU2020134947A (ru) Производные конденсированной циклической мочевины в антагонист crhr2